 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
|
|
|
|
Phase III
|
|
|
|
CALGB-80101
NCCTG-CALGB-80101, ECOG-CALGB-80101, CALGB-80101, NCT00052910
|
|
| |
A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-Line Therapy in Patients With Advanced Gastric Cancer
|
|
|
|
Phase III
|
|
|
|
AVF4200g
BO20904, NCT00548548
|
|
| |
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
|
|
|
|
Phase III
|
|
|
|
EGF110656
EGF110656-TRIO-CIRG 013, NCT00680901
|
|
| |
Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib
|
|
|
|
Phase III
|
|
|
|
IPI-504-06
NCT00688766
|
|
| |
Intraperitoneal Floxuridine in Gastric Carcinoma
|
|
|
|
Phase II, Phase I
|
|
|
|
2150
NCT00058916
|
|
| |
Low Dose Radiation Therapy as Chemosensitizer in GI/ Ovarian Tumors
|
|
|
|
Phase II, Phase I
|
|
|
|
22706
NCT00390182
|
|
| |
Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients
|
|
|
|
Phase II, Phase I
|
|
|
|
2004-0290
NCT00526110
|
|
| |
An Open-Label, Single-Center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
AT-101-CS-102
NCT00561197
|
|
| |
Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer
|
|
|
|
Phase II, Phase I
|
|
|
|
Pro00002207
SPS 151596, NCT00578071
|
|
| |
Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma
|
|
|
|
Phase II, Phase I
|
|
|
|
07326
NCT00667420
|
|
